SEP 20, 2019 08:21 AM PDT

Can CRISPR Technology Treat Alzheimer's?

WRITTEN BY: Annie Lennon

New drugs that seek to treat Alzheimer’s disease (AD) have a 99.6% failure rate. This makes it the only disease in the top 10 causes of death that cannot be prevented, slowed or cured. To this end, there is a lot of hope in new technology to finally overcome these hurdles. CRISPR technology in particular, with its ability to edit genes, is particularly promising. 

Yet, despite all the hype around CRISPR technology, the Food and Drug Administration (FDA) has only approved one CRISPR-related treatment so far, and not for AD. Instead, it seeks to treat various types of cancer, having entered clinical trials in May with the hope of measuring results from 18 patients (Fan: 2019). But why aren’t there any clinical trials to treat AD?

Creating a CRISPR technique to treat conditions of the central nervous system in people by itself poses many challenges. In particular, neuroscientists have struggled to find a safe and effective way to deliver CRISPR technology to targeted cells due to difficulties in designing a treatment that can safely cross the blood-brain barrier, traverse organelles and eventually end up in the targeted cell nuclei work (Fernandez: 2019). Only adding to this is the limited knowledge researchers have on the brain itself in comparison to other regions of the body, making researchers even more cautious of the technique (Rudin: 2018). 

Despite these difficulties however, CRISPR technology has nevertheless had some breakthroughs in possible treatments for AD. For example, a team of Korean researchers have created nanoparticles that act as delivery drones for transporting CRISPR to brain cells in people with Alzheimer’s. Their treatment works by turning off the Bace1 gene, known to stimulate amyloid beta production, which has been linked to Alzheimer’s cognitive effects (Park: 2019). 

So far, it seems to work well. After a single dose of the treatment, mice with characteristics of AD experienced significant reductions in their beta-amyloid levels, alongside signs of improved memory and learning. Although promising, the researchers feel that before human trials could begin, they need to confirm their results on higher primates too (ibid.). 

Meanwhile, CRISPR technology is also being used to advance our understanding in other areas of AD treatment. Researchers at the Institute of Molecular Pathology Biomarkers (IBPM) for example used CRISPR technology to identify a biomarker for the disease. Finding a deficiency in the protein STIM1 in the brain tissue of those with AD, they used CRISPR to silence the gene that allows STIM1 to be expressed to see whether a lack of the protein could be linked to Alzheimer’s. When inactivated, the researchers noticed the development of AD-like patterns, confirming a link between STIM1 and the disease, thus creating new avenues for research and eventual drug development (University of Extremadura: 2018). 

To conclude, although CRISPR shows promising signs for one day treating AD, further research on both how the disease functions, as well as how CRISPR may be delivered is required before treatments can properly be developed. In the meantime however, it is clear that the technique may still be used to develop our understanding of the disease and explore possibilities with other treatments too. 

 

Sources

 

Fan, Shelly: Singularity Hub 

Fernandez, Tara: Massive Science

Rudin, Mark: Idaho Statesman

University of Extremadura: Eureka Alert!

Park, Hanseul: Nature

About the Author
  • Writer with a keen interest in genetics, psychology, health and everything in between. Currently focused on the interplay of genetics and society to understand how to create meaningful interactions and environments.
You May Also Like
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Can Ecstasy Treat PTSD and Depression?
Ecstasy, also known as MDMA or “molly”, is a well-known substance known to induce feelings of euphoria and bliss, followed by a notorious, depr...
OCT 17, 2019
Health & Medicine
OCT 17, 2019
How Much Caffeine Can Trigger a Migraine?
Do you suffer from migraines? Your caffeine intake may be a trigger. Researchers from the Beth Israel Deaconess Medical Center (BIDMC), Brigham and Women&r...
OCT 17, 2019
Neuroscience
OCT 17, 2019
Scientists discover new pain-sensing organ in skin
Schwann cells are octopus-like cells in the nervous system that wrap around nerve cells, jelly-roll fashion, to form a special insulating layer. These cell...
OCT 17, 2019
Plants & Animals
OCT 17, 2019
Crows Are Incredibly Smart Birds
Many people don’t realize it, but animals can be particularly intelligent when it comes to matters of problem-solving. In this video, we see a lone c...
OCT 17, 2019
Chemistry & Physics
OCT 17, 2019
Scientists Developed Magnetic Nanoparticles that can Remotely Modulate Neural Circuits
Currently, neuroscience researchers rely heavily on invasive procedures to stimulate and study the neural activity of animals. A team of MIT scientists has...
OCT 17, 2019
Neuroscience
OCT 17, 2019
Living by the Sea is Better for Mental Health
Could how close you live to the sea have a positive impact on your mental health? For the first time, researchers from the University of Exeter have found ...
Loading Comments...